✦ LIBER ✦

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

✍ Scribed by Jabbour, E; Kantarjian, H; Jones, D; Talpaz, M; Bekele, N; O'Brien, S; Zhou, X; Luthra, R; Garcia-Manero, G; Giles, F

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Response to Imatinib mesylate in chronic

✍ Pratibha Sharma; Lalit Kumar; Sujata Mohanty; Vinod Kochupillai 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 122 KB

Occurrence of additional chromosome aber

✍ Schoch, C; Haferlach, T; Kern, W; Schnittger, S; Berger, U; Hehlmann, R; Hiddema 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 112 KB

Characteristics of BCR–ABL kinase domain

✍ YaZhen Qin; ShanShan Chen; Bin Jiang; Qian Jiang; Hao Jiang; JinLan Li; LingDi L 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 116 KB

Dendritic cells become BCR–ABL negative

✍ Wang, L; Butt, N M; Atherton, M G; Clark, R E 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 82 KB

Identification of a rare e8a2 BCR-ABL fu

✍ Cayuela, J M; Rousselot, P; Nicolini, F; Espinouse, D; Ollagnier, C; Bui-Thi, M 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 99 KB

Prolonged treatment with imatinib mesyla

✍ E. Cariani; M. Capucci; M. Micheletti; F. Spalenza; I. Zanella; A. Albertini; G. 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 114 KB